High Growth Tech Stocks To Watch This November 2024

In This Article:

As global markets navigate the uncertainties surrounding the incoming Trump administration, key indices like the S&P 500 and Nasdaq have experienced notable declines, reflecting investor caution amid potential policy shifts and inflationary pressures. In this environment, identifying high-growth tech stocks requires a focus on companies that demonstrate resilience through innovation and adaptability to evolving regulatory landscapes.

Top 10 High Growth Tech Companies

Name

Revenue Growth

Earnings Growth

Growth Rating

Yggdrazil Group

24.66%

85.53%

★★★★★★

eWeLLLtd

26.52%

27.53%

★★★★★★

Seojin SystemLtd

33.54%

52.43%

★★★★★★

Ascelia Pharma

76.15%

47.16%

★★★★★★

Medley

25.59%

31.50%

★★★★★★

Mental Health TechnologiesLtd

27.88%

79.61%

★★★★★★

Alnylam Pharmaceuticals

22.45%

70.66%

★★★★★★

TG Therapeutics

34.66%

56.48%

★★★★★★

Travere Therapeutics

31.75%

72.43%

★★★★★★

UTI

114.97%

134.60%

★★★★★★

Click here to see the full list of 1303 stocks from our High Growth Tech and AI Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Swedish Orphan Biovitrum

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Swedish Orphan Biovitrum AB (publ) is an integrated biotechnology company that focuses on researching, developing, manufacturing, and selling pharmaceuticals in haematology, immunology, and specialty care across Europe, North America, the Middle East, Asia, and Australia with a market capitalization of approximately SEK102.41 billion.

Operations: The company's revenue is primarily driven by its haematology segment, generating SEK15.58 billion, followed by immunology at SEK8.67 billion, and specialty care at SEK1.18 billion.

Swedish Orphan Biovitrum (SOBI) has demonstrated robust growth in the biotech sector, outpacing industry averages with a 26.9% earnings increase over the past year, significantly ahead of the biotech industry's -20.8% decline. This performance is underpinned by a strategic focus on rare diseases, as evidenced by promising phase 3 results from their VALIANT study showing a 68% reduction in proteinuria for kidney disease patients treated with pegcetacoplan. With R&D expenses aligning closely with innovative outcomes—evident from recent clinical successes—SOBI's commitment to research is likely to sustain its growth trajectory, further supported by an upwardly revised revenue forecast expecting mid-teens percentage growth for 2024 at CER. This positions SOBI favorably within a niche yet critical segment of healthcare, addressing unmet medical needs that could drive future expansion and market penetration.